Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
151
resultados
Última actualización
27/03/2025 [06:58:00]
Resumen de: EP4527291A2
A method and a system for improving the accuracy of a continuous glucose monitoring sensor by estimating a CGM signal at a time t+PH using a value of CGM at time t, using a short-time glucose prediction horizon to estimate the value of a CGM signal at a time t+PH with a noise estimation algorithm.
Resumen de: EP4527292A1
Provided is a body-attachable unit configured to be attached to and inserted into a body for measuring biometric information, the body-attachable unit including a housing formed so that a bottom surface is configured to be attached to skin, a printed circuit board (PCB) substrate, which is disposed in the housing, with a plurality of electrical contacts formed to protrude from a surface of the PCB substrate, and a sensor member including a sensor body part disposed in the housing and a sensor probe part formed and extended from a side of the sensor body part to protrude outward from the bottom surface of the housing and configured to be inserted into the skin if the housing is attached to the skin, and at least one of the plurality of electrical contacts is formed to make contact with the sensor body part to support the sensor body part, remaining of the plurality of electrical contacts are formed to be spaced apart from the sensor body part, and the sensor body part is to make contact with all of the plurality of electrical contacts by manipulation by a user.
Resumen de: AU2023271749A1
Disclosed are techniques, devices and computer products in which a processor is operable to access blood glucose measurement values and insulin data from a data memory. Based on the blood glucose measurement values the processor may be operable to identify high events that exceed an upper target blood glucose set point and low events in which blood glucose measurement values are below a lower target blood glucose set point. Rules may be applied to the high events and low events. Based on a result of the rules, high event patterns may be identified as well as a low event pattern. A respective pattern weight may be applied to each identified high event and each identified low and a graphical user interface may be populated with a number of high event patterns and for a number of low event patterns.
Resumen de: US2023301557A1
Embodiments of the present disclosure relate to systems, devices and methods for continuous glucose monitoring. In some embodiments, a continuous glucose monitoring (CGM) device is provided that includes a subcutaneous implantable electrochemical sensing probe (sensor). The sensor is planar and comprises counter and working electrodes that are deposited at both sides of the sensing probe. A biocompatible layer deposited at the entire sensor circumference minimizes inflammatory reaction. A reel to reel production process provides “per sensor” layers' deposition at predefined spots on a base sheet during displacement between production stations. Production processes are conducted initially at one side of the base sheet followed by production processes on the opposite side. Sensor by sensor working electrode surface areas and layers' thickness are measured and “per sensor” data (“dry” parameters) is stored according to base sheet identifiers that could be implemented by printed or etched markings or else by other means such as RFID. In addition, batch parameters are measured on a sample basis (in vitro “wet” parameters). A factory calibration algorithm analyzes “per lot” sample of sensors' performance (in vitro “wet” parameters in glucose solutions) as well as individual sensor measurement and combines the data in a calibration algorithm to calculate individual sensor calibration parameters and data is programmed back to the individual sensor.
Resumen de: EP4464242A2
The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.
Resumen de: US2025090052A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025090758A1
A botulinum toxin syringe having a barrel has volumetric marking graduations scaled at four units per 0.1 mL. These volumetric marking graduations allow for ease of unit conversion and can reduce the likelihood of overdosing or under dosing of botulinum toxin. The syringe may further comprise further volumetric marking graduations configured to be interchangeably used for administration of insulin or botulinum toxin. The syringe may further comprise further volumetric marking graduations configured for interchangeably use for administration of different types of botulinum toxin.
Resumen de: US2025090103A1
Conditions of pathophysiologic dysglycemia, associated with type 1 diabetes, can be detected early, including in children. Glycemia data is collected by continuous glucose monitoring devices connected to a cloud server. The server learns person-specific patterns of glycemia and trains a model accordingly, which may serve as a baseline for comparison or as the basis for prediction of future patterns. Such models are conditioned by risk factors and various concurrent activities such as exercise and consumption of sugars. Person-specific models trained at different time periods give different simulated patterns of glycemia. Deviations between the simulated patterns, or between the predicted and actual patterns, can indicate progression of pathophysiologic dysglycemia and type 1 diabetes. These models and comparisons can be further interpreted by the software to result in a reported recommendation for additional diagnostic testing or a reported conclusion of diagnosis and recommendation of preventative intervention.
Resumen de: US2025090082A1
There is a need for more effective and efficient predictive data analysis, such as more effective and efficient data analysis solutions for performing predictive monitoring of the glucose-insulin endocrine metabolic regulatory system.
Resumen de: US2025090753A1
Disclosed herein are techniques related to making trend based adjustments to insulin dosage. In some embodiments, the techniques may involve obtaining, based on glucose measurements performed on a person, a glucose value and a glucose rate of change (ROC). An initial insulin amount to deliver to the person is calculated based on this glucose value. However, an adjustment value can be obtained in response to a determination that the glucose value exceeds a glucose threshold, and that the glucose ROC exceeds an ROC threshold. The adjustment value represents an adjustment to be applied to the initial insulin amount when the glucose threshold and the ROC threshold are both exceeded. The adjustment value can be predetermined, based on earlier glucose measurements performed on the person. For instance, the adjustment value and the thresholds can be jointly determined through a computer simulation using a person-specific physiological model.
Resumen de: US2025090754A1
Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
Resumen de: US2025090053A1
The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation occurs in a stabilized state, thereby allowing more accurate blood glucose monitoring.
Resumen de: WO2025055546A1
The present application provides a tympanic membrane temperature measuring apparatus, a blood glucose measuring method, a system, and a device. First, a target tympanic membrane temperature is acquired; a target oral cavity temperature is estimated on the basis of a pre-established temperature correspondence between the tympanic membrane and the oral cavity; a temperature correspondence between blood glucose increments and oral cavity temperature increments is then established on the basis of a pre-calibrated invasive blood glucose value and an oral cavity calibration temperature, so as to calculate a target blood glucose increment; and finally, a target blood glucose value is calculated on the basis of the target blood glucose increment and the pre-calibrated invasive blood glucose value. In this way, impact of other factors on blood glucose measurement is reduced while increasing the apparent temperature in the blood glucose measurement process.
Resumen de: WO2025055545A1
The present application provides an eardrum temperature measuring apparatus, a blood sugar measuring method, a system, and a device. By means of a high-precision eardrum temperature measuring apparatus measuring multiple temperature points disposed in the ear canal, a target eardrum temperature is estimated without contacting the eardrum; next, based on the target eardrum temperature, a target oral temperature is estimated on the basis of a pre-established correspondence relationship between eardrum and oral cavity temperatures; then, by means of a pre-calibrated invasive blood sugar value and an oral calibration temperature, a temperature correspondence relationship between a blood sugar increment and an oral temperature increment is established, and a target blood sugar increment can be calculated; finally, based on the target blood sugar increment and the pre-calibrated invasive blood sugar value, a target blood sugar value is calculated, that is, by means of the precision measuring apparatus and the conversion relationships between multiple pieces of precision data, the accuracy and stability of blood sugar measurement are improved, the influence of external factors on blood sugar measurement is reduced, and the ability of a measurement process to resist interference is improved.
Resumen de: US2025094109A1
A continuous glucose monitor for wirelessly transmitting data relating to glucose value to a plurality of displays is disclosed, as well as systems and methods for limiting the number of display devices that can connect to a continuous glucose transmitter. In addition, security, including hashing techniques and a changing application key, can be used to provide secure communications between the continuous glucose transmitter and the displays. Also provided is a continuous glucose monitor and techniques for authenticating multiple displays, providing secure data transmissions to multiple displays, and coordinating the interaction of commands and data updates between multiple displays.
Resumen de: WO2025055788A1
An OCTA-based non-invasive continuous blood glucose measurement method and apparatus. The OCTA-based non-invasive continuous blood glucose measurement method comprises: performing continuous OCT scanning imaging on a target tissue region, then using a depth attenuation characteristic of an OCT signal to extract a three-dimensional scattering coefficient of the target tissue region, and generating a three-dimensional microvascular distribution of the target tissue region; then accurately distinguishing a blood scattering coefficient and a tissue scattering coefficient on the basis of the three-dimensional scattering coefficient and the three-dimensional microvascular distribution; using an electrochemical method to measure reference blood glucose concentrations at two moments, and finally, respectively combining the reference blood glucose concentrations with the blood scattering coefficient and the tissue scattering coefficient to achieve continuous measurement of a blood glucose concentration and an interstitial fluid glucose concentration. According to the method, on the basis of OCTA guidance, the synchronous measurement of the interstitial fluid glucose concentration is implemented while accurate measurement of the blood glucose concentration is implemented, and the method has a great heuristic significance for the optical non-invasive blood glucose measurement.
Resumen de: US2025095869A1
Presented herein is a handheld analyte measurement device. The analyte measurement device includes one or more software applications to help the user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with the handheld analyte measurement device.
Resumen de: US2025095862A1
In some examples, an apparatus, such as a mobile phone can include an input module such as a touch screen, a camera, a processor, and computer readable medium. The camera captures one or more images of a person. The processor can use a single machine learning model to estimate the human body features of the person based on the captured images, and use the human body features to generate a disease risk assessment value associated with diabetes and cardiovascular disease risks. The human body features can include at least one or more of: 3D body shape, or body shape indicators; and one or more of: blood flow, blood pressure, heart rate, respiratory rate, heart rate variability, cardiac workload, irregular heartbeats, or stress index. The machine learning model can be trained over a set of training images.
Resumen de: AU2025201387A1
A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.
Resumen de: EP4523621A2
A method for providing blood glucose data is provided. In response to a suspension of a continuous basal insulin delivery, by an insulin delivery pump, the method identifies a condition indicating continuing hypoglycemia that continues when basal insulin delivery is suspended; and performs an action, by the insulin delivery pump, based on identifying the condition.
Resumen de: US12251242B1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
Resumen de: EP4464242A2
The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.
Resumen de: US2019216405A1
The disclosure relates to a method and a system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level in a system having a data processing device provided with one or more processors. The method comprises steps of: receiving a glucose monitoring value by the data processing device, the glucose monitoring value indicating a glucose level sampled from a person in a bodily fluid in a glucose level measurement; receiving, by the data processing device, insulin bolus administration data indicating an insulin bolus of an insulin bolus administration; determining, by the data processing device, from an analysis of the glucose monitoring value, a carbohydrate intake event if one of the following is detected: the glucose monitoring value indicates a glucose level below a first threshold glucose level; and the glucose monitoring value indicates an elevated glucose level above a second threshold glucose level, and the insulin bolus indicated by the insulin bolus administration data is exceeding a corrective insulin bolus suitable for compensating for the elevated glucose level; and generating, by the data processing device, carbohydrate intake event data indicating the determined carbohydrate intake event. Further, a non-transitory computer readable medium is provided.
Resumen de: US2019216405A1
The disclosure relates to a method and a system for determining a carbohydrate intake event from glucose monitoring data indicative of a glucose level in a system having a data processing device provided with one or more processors. The method comprises steps of: receiving a glucose monitoring value by the data processing device, the glucose monitoring value indicating a glucose level sampled from a person in a bodily fluid in a glucose level measurement; receiving, by the data processing device, insulin bolus administration data indicating an insulin bolus of an insulin bolus administration; determining, by the data processing device, from an analysis of the glucose monitoring value, a carbohydrate intake event if one of the following is detected: the glucose monitoring value indicates a glucose level below a first threshold glucose level; and the glucose monitoring value indicates an elevated glucose level above a second threshold glucose level, and the insulin bolus indicated by the insulin bolus administration data is exceeding a corrective insulin bolus suitable for compensating for the elevated glucose level; and generating, by the data processing device, carbohydrate intake event data indicating the determined carbohydrate intake event. Further, a non-transitory computer readable medium is provided.
Nº publicación: WO2025054131A1 13/03/2025
Solicitante:
UNIV OF HOUSTON SYSTEM [US]
UNIV OF TRENTO [IT]
UNIVERSITY OF HOUSTON SYSTEM,
UNIVERSITY OF TRENTO
Resumen de: WO2025054131A1
A blood glucose monitoring system having an insulin pump operational to administer insulin to the subject, sensors associated with the subject and operational to measure the blood glucose levels of a subject, and a computing device in electronic communication with the insulin pump. The computing device includes computer readable storage mediums having program code embodied therewith. The computing device includes a closed-loop insulin delivery algorithm trained to predict the blood glucose level of the subject. The algorithm includes a data-driven multi-step- ahead blood glucose predictor integrated with a linear time-varying model predictive control law. The computing device includes programming instructions for feeding the subject's blood glucose level into the algorithm, using the algorithm to predict if the blood glucose level of the subject is expected to reach a level representing hypoglycemia or hyperglycemia, and transmitting insulin administration instructions to the insulin pump based on the prediction.
BOPI
Sede Electrónica
